Free data wipe software

BHUBANESWAR -- Indian Prime Minister Narendra Modi was inoculated with the first dose of a home-grown coronavirus vaccine on Monday, kicking off an expansion of the country’s immunisation campaign as infections rise in some big states. People above 60, and those who are 45 or more and suffering from certain medical conditions, are now eligible for the vaccinations. But some inoculation centres reported issues with the government’s Co-Win portal used to coordinate the drive, which could slow its progress. India, which has reported the highest number of COVID-19 cases after the United States, has so far vaccinated 12 million health and front-line workers since starting its immunisation programme in mid-January. It wants to cover 300 million of its 1.35 billion people by August. “I appeal to all those who are eligible to take the vaccine,” 70-year-old Modi said on Twitter, posting a picture of him getting the shot at a government hospital in New Delhi. “Together, let us make India COVID-19 free!” The government said last week it would let people choose their vaccination centres, effectively letting beneficiaries pick either the home-grown COVAXIN shot or the AstraZeneca vaccine, unlike earlier. The inoculation campaign has run slower than expected due to a reluctance of health and front-line workers to take COVAXIN, which was approved without late-stage efficacy data. Only about 11% of vaccinated people have opted for the product developed by Bharat Biotech and the state-run Indian Council of Medical Research. Bharat Biotech has said efficacy data from a late-stage trial on nearly 26,000 volunteers who took COVAXIN will be out soon. The company, along with India’s drug regulator, says COVAXIN is safe and effective, based on early and intermediate studies. “Inspired and humbled by Hon’ble PM’s remarkable commitment to build an Aatmanirbhar Bharat,” Bharat Biotech said in reply to Modi’s tweet, referring to his self-reliance pitch to back local products. …

[Read more...] about Modi takes home-grown vaccine as India widens immunisation drive

LONDON -- In October 2020, Miami-based art collector Pablo Rodriguez-Fraile spent almost $67,000 on a 10-second video artwork that he could have watched for free online. Last week, he sold it for $6.6 million. The video by digital artist Beeple, whose real name is Mike Winkelmann, was authenticated by blockchain, which serves as a digital signature to certify who owns it and that it is the original work. It’s a new type of digital asset - known as a non-fungible token (NFT) - that has exploded in popularity during the pandemic as enthusiasts and investors scramble to spend enormous sums of money on items that only exist online. Blockchain technology allows the items to be publicly authenticated as one-of-a-kind, unlike traditional online objects which can be endlessly reproduced. “You can go in the Louvre and take a picture of the Mona Lisa and you can have it there, but it doesn’t have any value because it doesn’t have the provenance or the history of the work,” said Rodriguez-Fraile, who said he first bought Beeple’s piece because of his knowledge of the U.S.-based artist’s work. “The reality here is that this is very, very valuable because of who is behind it.” Examples of NFTs range from digital artworks and sports cards to pieces of land in virtual environments or exclusive use of a cryptocurrency wallet name, akin to the scramble for domain names in the early days of the internet.“Non-fungible” refers to items that cannot be exchanged on a like-for-like basis, as each one is unique - in contrast to “fungible” assets like dollars, stocks or bars of gold. The computer-generated video sold by Rodriguez-Fraile shows what appears to be a giant Donald Trump collapsed on the ground, his body covered in slogans, in an otherwise idyllic setting. OpenSea, a marketplace for NFTs, said it has seen monthly sales volume grow to $86.3 million so far in February, as of Friday, from $8 million in January, citing blockchain data. Monthly sales were at $1.5 …

[Read more...] about How a 10-second video clip sold for $6.6 million

>>> VND20 billion offered for home-grown COVID-19 vaccine clinical trial study >>> Nearly 300 volunteers in Long An engage in second-stage trials of Nano Covax Protecting against new SARS-CoV-2 variants from the UK and South Africa IVAC's COVIVAC vaccine research project started from May 2020 on the basis of cooperation with the relevant universities, research institutes and international organisations. IVAC Director Dr. Duong Huu Thai shared that the vaccine phase 1 and phase 2 clinical research protocols have been approved by the National Ethical Council in Biomedical Research and the Ethical Councils at grassroots level. IVAC is scheduled to kickstart the clinical trials at National Institute of Hygiene and Epidemiology (NIHE) and Hanoi Medical University in early March and will conclude by this October. According to Dr. Thai, volunteers participating in the study include 120 healthy persons, aged 18-59, both male and female. They will receive two injections of 0.5 ml each (vaccine or placebo injection) 28 days apart. Phase 1 will study the safety and immunogenicity on four groups of different doses: 1mcg, 3mcg and 10mcg of Protein S antigen without adjuvants and 1mcg with adjuvants, along with a placebo control group (using vaccine-free ingredients) to evaluate safety and immune response to select the two optimal vaccine groups, then moving to Phase 2. After the 1st injection, the volunteers will be medically monitored for 24 hours at the Hanoi Medical University. After the second, medical monitoring time will be four hours. Phase 2 will be conducted at the Medical Centre of Vu Thu District, Thai Binh Province. Volunteers will include 300 healthy people, aged 18-75 (of which age 60-75 accounts for about one third), both male and female. After Phase 1 (after 43 days of injection), if the immunosecurity results are good and the optimal dose is selected, the vaccine will continue to Phase 2. Volunteers will receive …

[Read more...] about Vietnam to commence human trials on second home-grown COVID-19 vaccine in early March